Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

medicines access

This page shows the latest medicines access news and features for those working in and with pharma, biotech and healthcare.

NICE launches consultation on its methods of drug evaluation

NICE launches consultation on its methods of drug evaluation

Through the CDF, NICE can appraise drugs while providing interim funding for up to two years to give patients access to drugs that have either a draft recommendation for routine use ... As we develop a new regulatory and access environment for medicines,

Latest news

More from news
Approximately 4 fully matching, plus 440 partially matching documents found.

Latest Intelligence

  • Growing evidence supports the important role of biosimilars in healthcare Growing evidence supports the important role of biosimilars in healthcare

    Access to healthcare, including affordable medicines, remains a top concern across the US. ... As more biosimilars enter the US market, patients treated with biologic medicines will have access to a broader set of more affordable treatment options.

  • Rebranding in an evolving world Rebranding in an evolving world

    patients by enhancing the critical medicines they depend on, broadening patient access and improving health outcomes around the world. ... 180+ molecules to specialised patient populations around the world, while simultaneously focusing on

  • Rethinking our approach to infectious disease preparedness Rethinking our approach to infectious disease preparedness

    NHS England will now pay pharma companies a guaranteed amount for access to new drugs to treat resistant infections for up to ten years, a reward potentially totalling £100m. ... Both the UK and US models treat access to novel antibiotic medicines like

  • NICE – but not enough NICE – but not enough

    This falls to 30 days for products included in the Early Access to Medicines Scheme (EAMS) or those designated for Fast Track Appraisal. ... Medicines that have open access – ie, there’s no restriction on their use – tend to perform better than

  • Addressing the payer-regulator evidence gap in early-stage cancer Addressing the payer-regulator evidence gap in early-stage cancer

    disease. Is there a way to accelerate patient access to medicines for earlystage cancers in the interim? ... Jason Ward is Head of Haematology and Group Director, Strategy, Policy &Operations, Oncology Market Access and Pricing at AstraZeneca.

More from intelligence
Approximately 0 fully matching, plus 97 partially matching documents found.

Latest appointments

  • Pfizer’s Alan Maine moves to Edelman Pfizer’s Alan Maine moves to Edelman

    Maine, who previously served as head of policy and public affairs at Pfizer UK, was responsible for government affairs and market access policy development activity, covering both corporate and therapy area ... During his time at Pfizer, Maine also

  • Sobi names Holly May VP of sales and marketing, US Sobi names Holly May VP of sales and marketing, US

    May’s new role will see her lead the biopharma’s commercial team in bringing Sobi’s medicines to the country. ... She will also collaborate with the operations and patient access team to ensure the medicines are accessible to as many appropriate

  • Inceptua Medicines Access appoints senior new-hires Inceptua Medicines Access appoints senior new-hires

    Multipharma’s new speciality business unit, Inceptua has appointed Ruth Rostron as its new senior project manager, a role that will see her focus on design and implementation of medicines access

  • Sandoz UK promotes Tim de Gavre to country head Sandoz UK promotes Tim de Gavre to country head

    As a company, Sandoz has an exciting portfolio of medicines and future product pipeline. ... I look forward to working with the Sandoz team, and in partnership with the NHS to help patients access these important medicines.”.

  • Takeda UK & Ireland appoints market access director Takeda UK & Ireland appoints market access director

    Takeda UK &Ireland has appointed Peter Wheatley Price as market access director, succeeding Ross Selby who moves to head the firm's new US-based global pricing, market access and health ... He also brings experience form Boehringer Ingelheim, where he

More from appointments
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest from PMHub

  • 2020 - a year to remember or forget? 2020 - a year to remember or forget?

    All while we were relocating our offices to our homes. But as we all know, the world of healthcare doesn’t ever stop – patients still need access to medicines and support ... HCPs had to adjust how they delivered care (often though telemedicine) and

  • It's out - so what? It's out - so what?

    When working to ensure access to affordable medicines to patients, will the EU institutions focus on prices – a message that seems to be coming through from the Commission? ... Hanover’s IPMA team is a leading international policy and market access

  • Aurora celebrates 15 years of improving lives Aurora celebrates 15 years of improving lives

    Claire Eldridge, CEO, comments: “It has been a privilege to work with our clients to help realise the potential of their interventions, to ensure patient access to innovation and to promote ... Worked to speed up access to innovative medicines and

  • Let's be ambitious for patients and life sciences investment in Global Britain Let's be ambitious for patients and life sciences investment in Global Britain

    The current NICE Methods Review is an opportunity that should be grasped by Government to enhance patient access to new medicines and simultaneously boost the attractiveness of the UK to the ... A triple win is on offer. Patients gain faster and fuller

  • Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?

    This eventually could lead to delays in access to medicines for patients, especially for novel therapies. ... more than 15 people can access [a virtual preceptorship] all at the same time, and this could have a massive impact in the diagnosis of rare

More from PMHub
Approximately 0 fully matching, plus 23 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Quick links

Infographics

Multimedia